LeMaitre Vascular, Inc. $LMAT Stock Position Lifted by Synovus Financial Corp

Key Points

• Synovus Financial Corp increased its stake in LeMaitre Vascular, Inc. by 65.5% in the first quarter, owning 9,837 shares valued at approximately $825,000 by the end of the reporting period.
• LeMaitre Vascular reported a quarterly earnings per share of $0.60, surpassing analysts' expectations, and a revenue of $63.15 million, which was up 15% year-over-year.
• The company announced a quarterly dividend of $0.20 per share, resulting in an annualized yield of 0.8%, with a payout ratio of approximately 38.83%.

Synovus Financial Corp raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 65.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,837 shares of the medical instruments supplier's stock after purchasing an additional 3,893 shares during the period. Synovus Financial Corp's holdings in LeMaitre Vascular were worth $825,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Opal Wealth Advisors LLC acquired a new position in shares of LeMaitre Vascular in the 1st quarter valued at approximately $26,000. NBC Securities Inc. acquired a new position in shares of LeMaitre Vascular in the 1st quarter valued at approximately $36,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of LeMaitre Vascular in the 1st quarter valued at approximately $50,000. US Bancorp DE raised its position in shares of LeMaitre Vascular by 36.0% in the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock valued at $117,000 after purchasing an additional 368 shares in the last quarter. Finally, Cetera Investment Advisers raised its position in shares of LeMaitre Vascular by 11.5% in the 4th quarter. Cetera Investment Advisers now owns 2,753 shares of the medical instruments supplier's stock valued at $254,000 after purchasing an additional 284 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Cantor Fitzgerald upped their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target on the stock in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $97.60.

LeMaitre Vascular Stock Performance

Shares of LMAT stock traded up $0.09 on Friday, hitting $95.36. 93,841 shares of the stock traded hands, compared to its average volume of 223,607. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. The company has a market capitalization of $2.16 billion, a PE ratio of 46.29, a PEG ratio of 2.45 and a beta of 0.79. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58. The company's fifty day moving average is $87.40 and its 200 day moving average is $86.33.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. The firm had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm's revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.52 EPS. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Thursday, August 21st. LeMaitre Vascular's dividend payout ratio is presently 38.83%.

Insider Buying and Selling

In related news, Director David B. Roberts sold 10,815 shares of the company's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the transaction, the director directly owned 17,976 shares in the company, valued at $1,660,802.64. This represents a 37.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John A. Roush sold 6,561 shares of the company's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the transaction, the director owned 2,916 shares of the company's stock, valued at approximately $269,875.80. The trade was a 69.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 120,815 shares of company stock valued at $11,280,206 in the last 90 days. Corporate insiders own 9.50% of the company's stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.